Overcoming 5-Fu resistance of colon cells through inhibition of glut1 by the specific inhibitor WZB117

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 17, 2014, Pages 7037-7041

  Liu, Wei ^a   Fang, Yong ^a   Wang, Xiao Tong ^a   Liu, Ju ^a   Dan, Xing ^b   Sun, Lu Lu ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b Northeast Pharmaceutical Group Co Ltd   (China)

Author keywords

5 fluorouracil; Colon cancer; Glut1; Specific inhibitor; WZB117

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; GLUCOSE TRANSPORTER 1; HYDROXYBENZOIC ACID DERIVATIVE; SLC2A1 PROTEIN, HUMAN; WZB117;

ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; COLONIC NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; HT 29 CELL LINE; HUMAN; METABOLISM; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GLUCOSE TRANSPORTER TYPE 1; HT29 CELLS; HUMANS; HYDROXYBENZOATES; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84907262693     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.17.7037     Document Type: Article

References (21)

1. Beck A, Etienne MC, Cheradame S, et al (1994). A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer, 30, 1517-22.
2. Boyer J, McLean EG, Aroori S, et al (2004). Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res, 10, 2158-67.
3. Carvalho KC, Cunha IW, Rocha RM, et al (2011). GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. Clinics, 66, 965-72.
4. Curtin NJ, Harris AL, Aherne GW (1991). Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole. Cancer Res, 51, 2346-52.
5. DeBraud F, Munzone E, Nole F, et al (1998). Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil. Am J Clin Oncol, 21, 279-83.
6. Herrmann R (1996). 5-Fluorouracil in colorectal cancer, a never ending story. Ann Oncol, 7, 551-2.
7. Hur H, Xuan Y, Kim YB, et al (2013). Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential therapeutic target. Int J Oncol, 42, 44-54.
8. Li LJ, Li GD, Wei HL, et al (2014). Insulin resistance reduces sensitivity to Cis-platinum and promotes adhesion, migration and invasion in HepG2 cells. Asian Pac J Cancer Prev, 15, 3123-8.
9. Liu Y, Cao Y, Zhang W, et al (2012). A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther, 11, 1672-82.
10. Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer, 3, 330-8.
11. Peters GJ, van Triest B, Backus HH, et al (2000). Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed. Eur J Cancer, 36, 916-24.
12. Subbarayan PR, Lee K, Ardalan B (2010). Arsenic trioxide suppresses thymidylate synthase in 5-FU-resistant colorectal cancer cell line HT29 In Vitro re-sensitizing cells to 5-FU. Anticancer Res, 30, 1157-62.
13. Vander HM, Cantley LC, Thompson CB (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science, 324, 1029-33.
14. Wang FS, Aschele C, Sobrero A, et al (1993). Decreased folylpolyglutamate synthetase expression: a novel mechanism of fluorouracil resistance. Cancer Res, 53, 3677-80.
15. Wang YD, Li SJ, Liao JX (2013). Inhibition of glucose transporter 1 (GLUT1) chemosensitized head and neck cancer cells to cisplatin. Technol Cancer Res Treat, 12, 525-35.
16. Wood TE, Dalili S, Simpson CD, et al (2008). A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death. Mol Cancer Ther, 7, 3546-55.
17. Wu CH, Ho YS, Tsai CY, et al (2009). In vitro and in vivo study of phloretin-induced apoptosis in human liver cancer cells involving inhibition of type II glucose transporter. Int J Cancer, 124, 2210-9.
18. Zhang N, Yin Y, Xu SJ, et al (2008). 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules, 13, 1551-69.
19. Zhao Y, Butler EB, Tan M (2013). Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis, 4, 532.
20. Zhao Y, Liu H, Liu Z, et al (2011). Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res, 71, 4585-97.
21. Zhao L, Wang WJ, Zhang JN, et al (2014). 5-Fluorouracil and Interleukin-2 immunochemotherapy enhances immunogenicity of Non-Small cell lung cancer A549 cells through upregulation of NKG2D ligands. Asian Pac J Cancer Prev, 15, 4039-44.